Order Article Reprints

Harahap AS, Subekti I, Panigoro SS, Asmarinah, Lisnawati, Werdhani RA, Agustina H, Khoirunnisa D, Mutmainnah M, Gultom FL, et al. Developing Models to Predict BRAFV600E and RAS Mutational Status in Papillary Thyroid Carcinoma Using Clinicopathological Features and pERK1/2 Immunohistochemistry Expression. Biomedicines. 2023; 11(10):2803. https://doi.org/10.3390/biomedicines11102803

Harahap, Agnes Stephanie, Imam Subekti, Sonar Soni Panigoro, Asmarinah, Lisnawati, Retno Asti Werdhani, Hasrayati Agustina, Dina Khoirunnisa, Mutiah Mutmainnah, Fajar Lamhot Gultom, and et al. 2023. "Developing Models to Predict BRAFV600E and RAS Mutational Status in Papillary Thyroid Carcinoma Using Clinicopathological Features and pERK1/2 Immunohistochemistry Expression" Biomedicines 11, no. 10: 2803. https://doi.org/10.3390/biomedicines11102803

Harahap, A. S., Subekti, I., Panigoro, S. S., Asmarinah, Lisnawati, Werdhani, R. A., Agustina, H., Khoirunnisa, D., Mutmainnah, M., Gultom, F. L., Assadyk, A. H., & Ham, M. F. (2023). Developing Models to Predict BRAFV600E and RAS Mutational Status in Papillary Thyroid Carcinoma Using Clinicopathological Features and pERK1/2 Immunohistochemistry Expression. Biomedicines, 11(10), 2803. https://doi.org/10.3390/biomedicines11102803